The grant seeks to enhance cancer research by using advanced molecular imaging to gain insights into inflammation dynamics in vivo.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Resubmission) | June 5, 2027 (New) | July 5, 2027 (Resubmission) | October 5, 2027 (New) | November 5, 2027 (Resubmission) | January 7, 2028 (Closing date)
Funding Amounts: $500,000 award ceiling; application budgets below $500,000 in annual direct costs; up to 5 years
Summary: Supports interdisciplinary R01 research using molecular imaging to understand cancer-associated inflammation in vivo.
Key Information: Multiple principal investigators spanning cancer basic science and imaging science are required; clinical trials are not allowed.
The National Cancer Institute (NCI), part of NIH, supports development and application of current and emerging molecular imaging methods to investigate cancer inflammation in vivo. PAR-24-311 funds research that monitors specific cell populations or signaling pathways to explain dynamic relationships between inflammation and tumor behavior. The goal is to generate mechanistic insights that accelerate tumor-specific therapeutic approaches and improve monitoring of treatment responses.
The program emphasizes integrated, hypothesis-driven collaboration between cancer biology, immunology, and imaging researchers. Supported approaches include targeted probes, reporter genes, quantitative multimodal and multiscale imaging, and adaptation of imaging tools developed for other inflammatory diseases. Combining whole-organism imaging with multi-omics, in vitro, or ex vivo methods is encouraged when it addresses mechanistic hypotheses about cancer-associated inflammation.